Tuberculosis risk factors: Difference between revisions
| Line 7: | Line 7: | ||
==Risk Factors== | ==Risk Factors== | ||
In primary TB disease—1 to 5% of cases—this occurs soon after infection. However, in the majority of cases, a latent infection occurs that has no obvious symptoms. These dormant bacilli can produce tuberculosis in 2 to 23% of these latent cases, often many years after infection.<ref name=Parrish_1998>{{cite journal |author=Parrish N, Dick J, Bishai W |title=Mechanisms of latency in Mycobacterium tuberculosis |journal=Trends Microbiol |volume=6 |issue=3 |pages=107-12 |year=1998 | pmid = 9582936}}</ref> The risk of reactivation increases with immunosuppression, such as that caused by infection with HIV. In patients co-infected with [[HIV]], the risk of reactivation increases to 10% per year. | In primary TB disease—1 to 5% of cases—this occurs soon after infection. However, in the majority of cases, a latent infection occurs that has no obvious symptoms. These dormant bacilli can produce tuberculosis in 2 to 23% of these latent cases, often many years after infection.<ref name=Parrish_1998>{{cite journal |author=Parrish N, Dick J, Bishai W |title=Mechanisms of latency in Mycobacterium tuberculosis |journal=Trends Microbiol |volume=6 |issue=3 |pages=107-12 |year=1998 | pmid = 9582936}}</ref> The risk of reactivation increases with [[immunosuppression]], such as that caused by infection with HIV. In patients co-infected with [[HIV]], the risk of reactivation increases to 10% per year. | ||
Other conditions that increase risk include drug injection, mainly due to the lifestyle of IV drug users; recent TB infection or a history of inadequately treated TB; chest X-ray suggestive of previous TB, showing fibrotic lesions and nodules; [[diabetes mellitus]]; [[silicosis]]; prolonged [[corticosteroid]] therapy and other immunosuppressive therapy; head and neck cancers; [[hematology|hematologic]] and [[Reticuloendothelial system|reticuloendothelial]] diseases, such as [[leukemia]] and [[Hodgkin's lymphoma|hodgkin's disease;]] end-stage kidney disease; intestinal bypass or [[gastrectomy]]; chronic [[malabsorption]] syndromes; or low body weight. | Other conditions that increase risk include drug injection, mainly due to the lifestyle of IV drug users; recent TB infection or a history of inadequately treated TB; chest X-ray suggestive of previous TB, showing fibrotic lesions and nodules; [[diabetes mellitus]]; [[silicosis]]; prolonged [[corticosteroid]] therapy and other immunosuppressive therapy; head and neck cancers; [[hematology|hematologic]] and [[Reticuloendothelial system|reticuloendothelial]] diseases, such as [[leukemia]] and [[Hodgkin's lymphoma|hodgkin's disease;]] [[end-stage kidney disease]]; intestinal bypass or [[gastrectomy]]; chronic [[malabsorption]] syndromes; or low body weight. | ||
Some drugs, including [[rheumatoid arthritis]] drugs that work by blocking [[tumor necrosis factor-alpha]] (an inflammation-causing [[cytokine]]), raise the risk of activating a latent infection due to the importance of this cytokine in the immune defense against TB.<ref name=Mutlu_2006>{{cite journal |author=Mutlu G, Mutlu E, Bellmeyer A, Rubinstein I |title=Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy |journal=Am J Med |volume=119 |issue=8 |pages=639-46 |year=2006 | pmid = 16887405}}</ref> | Some drugs, including [[rheumatoid arthritis]] drugs that work by blocking [[tumor necrosis factor-alpha]] (an inflammation-causing [[cytokine]]), raise the risk of activating a latent infection due to the importance of this cytokine in the immune defense against TB.<ref name=Mutlu_2006>{{cite journal |author=Mutlu G, Mutlu E, Bellmeyer A, Rubinstein I |title=Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy |journal=Am J Med |volume=119 |issue=8 |pages=639-46 |year=2006 | pmid = 16887405}}</ref> | ||
Revision as of 19:08, 2 January 2013
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis risk factors On the Web |
|
American Roentgen Ray Society Images of Tuberculosis risk factors |
|
Risk calculators and risk factors for Tuberculosis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]
Overview
Progression from TB infection to TB disease occurs when the TB bacilli overcome the immune system defenses and begin to multiply.
Risk Factors
In primary TB disease—1 to 5% of cases—this occurs soon after infection. However, in the majority of cases, a latent infection occurs that has no obvious symptoms. These dormant bacilli can produce tuberculosis in 2 to 23% of these latent cases, often many years after infection.[1] The risk of reactivation increases with immunosuppression, such as that caused by infection with HIV. In patients co-infected with HIV, the risk of reactivation increases to 10% per year.
Other conditions that increase risk include drug injection, mainly due to the lifestyle of IV drug users; recent TB infection or a history of inadequately treated TB; chest X-ray suggestive of previous TB, showing fibrotic lesions and nodules; diabetes mellitus; silicosis; prolonged corticosteroid therapy and other immunosuppressive therapy; head and neck cancers; hematologic and reticuloendothelial diseases, such as leukemia and hodgkin's disease; end-stage kidney disease; intestinal bypass or gastrectomy; chronic malabsorption syndromes; or low body weight.
Some drugs, including rheumatoid arthritis drugs that work by blocking tumor necrosis factor-alpha (an inflammation-causing cytokine), raise the risk of activating a latent infection due to the importance of this cytokine in the immune defense against TB.[2]
Twin studies in the 1950's showed that the course of TB infection was highly dependent on the genetics of the patient. At that time, it was rare that one identical twin would die and the other live.[3]
References
- ↑ Parrish N, Dick J, Bishai W (1998). "Mechanisms of latency in Mycobacterium tuberculosis". Trends Microbiol. 6 (3): 107–12. PMID 9582936.
- ↑ Mutlu G, Mutlu E, Bellmeyer A, Rubinstein I (2006). "Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy". Am J Med. 119 (8): 639–46. PMID 16887405.
- ↑ New Scientist, 16 June 2007 [1]